{"id":314304,"date":"2020-01-24T18:35:29","date_gmt":"2020-01-25T02:35:29","guid":{"rendered":"https:\/\/nai500.com\/blog\/2020\/01\/beigenes-tislelizumab-could-challenge-mercks-keytruda\/"},"modified":"2020-01-24T18:35:50","modified_gmt":"2020-01-25T02:35:50","slug":"%e9%bb%98%e5%85%8b%e7%9a%84-keytruda-%e8%bf%8e%e6%8c%91%e6%88%98%e7%99%be%e6%b5%8e%e7%a5%9e%e5%b7%9e-tislelizumab-%e4%b8%8e%e4%b9%8b%e4%ba%89%e9%94%8b","status":"publish","type":"post","link":"https:\/\/nai500.com\/zh-hans\/blog\/2020\/01\/%e9%bb%98%e5%85%8b%e7%9a%84-keytruda-%e8%bf%8e%e6%8c%91%e6%88%98%e7%99%be%e6%b5%8e%e7%a5%9e%e5%b7%9e-tislelizumab-%e4%b8%8e%e4%b9%8b%e4%ba%89%e9%94%8b\/","title":{"rendered":"\u9ed8\u514b\u7684Keytruda\u8fce\u6311\u6218\uff0c\u767e\u6d4e\u795e\u5ddeTislelizumab\u4e0e\u4e4b\u4e89\u950b"},"content":{"rendered":"<p>\u5728\u4e2d\u56fd\u5317\u4eac\u548c\u9a6c\u8428\u8bf8\u585e\u5dde\u5251\u6865\u8bbe\u6709\u529e\u4e8b\u5904\u7684\u767e\u6d4e\u795e\u5dde\u672c\u5468\u65e9\u4e9b\u65f6\u5019\u5ba3\u5e03\u4e86\u5176\u6297PD-1\u6297\u4f53\u66ff\u96f7\u5229\u73e0\u5355\u6297\uff08Tislelizumab\uff09\u8054\u5408\u4e24\u79cd\u5316\u7597\u836f\u7269\u6cbb\u7597\u9cde\u72b6\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff08NSCLC\uff09\u7684\u91cd\u8981III\u671f\u8bd5\u9a8c\u7ed3\u679c\u3002Tislelizumab\u662f\u4e00\u79cd\u68c0\u67e5\u70b9\u6291\u5236\u5242\uff0c\u5728\u8ba1\u5212\u7684\u4e2d\u671f\u5206\u6790\u4e2d\u8fbe\u5230\u4e86\u6539\u5584\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\uff08PFS\uff09\u7684\u4e3b\u8981\u7ec8\u70b9\u3002\u5982Tislelizumab\u83b7\u6279\uff0c\u5b83\u5c06\u4e0e\u68c0\u67e5\u70b9\u6291\u5236\u5242\u5e02\u573a\u7684\u4e3b\u8981\u53c2\u4e0e\u8005\u9ed8\u514b\u53ca\u5176Keytruda\uff08pembrolizumab\uff09\u7ade\u4e89\u3002<\/p>\n<p>\u767e\u6d4e\u795e\u5dde\u8868\u793a\u8ba1\u5212\u5728\u4e2d\u56fd\u5bfb\u6c42\u6279\u51c6Tislelizumab\u3002Tislelizumab\u6b64\u524d\u5df2\u7ecf\u88ab\u6279\u51c6\u7528\u4e8e\u6cbb\u7597\u5148\u524d\u5df2\u63a5\u53d7\u8fc7\u4e24\u6b21\u764c\u75c7\u6cbb\u7597\u7684\u970d\u5947\u91d1\u6dcb\u5df4\u7624\u60a3\u8005\u3002\u53bb\u5e74\uff0c\u9ed8\u514b\uff08Merck\uff09\u7684Keytruda\u88ab\u6279\u51c6\u7528\u4e8e\u4e2d\u56fd\u7684NSCLC\u3002<\/p>\n<p>\u9ed8\u514b\u7684Keytruda\u6709\u671b\u53d6\u4ee3\u4e16\u754c\u4e0a\u6700\u7545\u9500\u7684\u836f\u7269\u3002\u8be5\u5934\u8854\u76ee\u524d\u5c5e\u4e8e\u827e\u4f2f\u7ef4\u7684Humira\uff0c\u8be5\u516c\u53f8\u6b63\u9762\u4e34\u65e5\u76ca\u6fc0\u70c8\u7684\u7ade\u4e89\u548c\u4e13\u5229\u5230\u671f\u3002\u4f3c\u4e4eKeytruda\u5927\u7ea6\u6bcf\u4e2a\u661f\u671f\u90fd\u88ab\u6279\u51c6\u7528\u4e8e\u65b0\u7684\u9002\u5e94\u75c7\u3002\u5c3d\u7ba1\u5e02\u573a\u4e0a\u786e\u5b9e\u5b58\u5728\u5176\u4ed6\u68c0\u67e5\u70b9\u6291\u5236\u5242\uff0c\u4f46\u6ca1\u6709\u54ea\u4e00\u79cd\u7279\u522b\u63a5\u8fd1Keytruda\u7684\u7edf\u6cbb\u5730\u4f4d\u3002<\/p>\n<p>\u5728\u767e\u6d4e\u795e\u5dde\u8bd5\u9a8c\u4e2d\uff0c\u5148\u524d\u672a\u63a5\u53d7\u6cbb\u7597\u7684\u665a\u671f\u9cde\u72b6NSCLC\u60a3\u8005\u63a5\u53d7\u4e86Tislelizumab\u8054\u5408\u7d2b\u6749\u9187\u548c\u5361\u94c2\u8054\u5408\u6cbb\u7597\u3002\u6839\u636e\u9884\u5148\u8ba1\u5212\u7684\u4e2d\u671f\u5206\u6790\uff0c\u4e0e\u5355\u72ec\u5316\u7597\u76f8\u6bd4\uff0c\u8be5\u8bd5\u9a8c\u7684\u4e24\u4e2aTislelizumab\u6cbb\u7597\u7ec4\u5747\u901a\u8fc7\u4e86\u7597\u6548\u8fb9\u754c\u3002<\/p>\n<p>\u767e\u6d4e\u795e\u5dde\u514d\u75ab\u80bf\u7624\u5b66\u533b\u5b66\u5b98 Yong Ben\u8bf4\uff1a\u201cTislelizumab\u6700\u8fd1\u5728\u4e2d\u56fd\u88ab\u6279\u51c6\u7528\u4e8e\u590d\u53d1\u6027\u6216\u96be\u6cbb\u6027\u7ecf\u5178\u970d\u5947\u91d1\u6dcb\u5df4\u7624\u60a3\u8005\uff0c\u6211\u4eec\u62e5\u6709\u5e7f\u6cdb\u7684\u5f00\u53d1\u8ba1\u5212\uff0c\u67095,000\u4f8b\u60a3\u8005\u53c2\u52a0\u4e86\u8d85\u8fc725\u4f8btislelizumab\u7814\u7a76\uff0c\u5305\u62ec15\u9879\u53ef\u80fd\u542f\u7528\u6ce8\u518c\u7684\u8bd5\u9a8c\u3002\u6211\u4eec\u5bf9Tislelizumab\u5728\u8be5III\u671f\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\u663e\u793a\u7684\u4ee4\u4eba\u4fe1\u670d\u7684\u7ed3\u679c\u4ee5\u53ca\u5176\u5728\u4e2d\u56fd\u665a\u671f\u9cde\u72b6NSCLC\u60a3\u8005\u4e2d\u4f5c\u4e3a\u4e00\u7ebf\u6cbb\u7597\u7684\u6f5c\u5728\u7528\u9014\u611f\u5230\u975e\u5e38\u5174\u594b\u3002\u6211\u4eec\u671f\u5f85\u7ee7\u7eed\u8fdb\u884cTislelizumab\u6cbb\u7597\u80ba\u764c\u4e2d\u7684\u5f00\u53d1\u8ba1\u5212\uff0c\u5176\u4e2d\u5305\u62ec\u5176\u4ed6\u4e09\u9879III\u671f\u8bd5\u9a8c\uff0c\u5e76\u62a5\u544a\u66f4\u591a\u6570\u636e\u3002\u201d<\/p>\n<p>\u4e0e\u5927\u591a\u6570\u897f\u65b9\u56fd\u5bb6\u4e0d\u540c\uff0c\u4e2d\u56fd\u7684\u80ba\u764c\u53d1\u75c5\u7387\u6b63\u5728\u4e0a\u5347\u3002 2018\u5e74\uff0c\u4e2d\u56fd\u7ea6\u6709770,000\u4f8b\u80ba\u764c\u65b0\u75c5\u4f8b\uff0c2018\u5e74\u5168\u56fd\u7ea6\u6709690,500\u4f8b\u6b7b\u4ea1\u3002NSCLC\u662f\u4e2d\u56fd\u6700\u5e38\u89c1\u7684\u80ba\u764c\u5f62\u5f0f\u3002<\/p>\n<p>Tislelizumab\u6700\u521d\u4e8e2017\u5e74\u88abCelgene\u6536\u8d2d\uff0c\u4f46Celgene\u5c06\u6743\u5229\u5f52\u8fd8\u4e86\u767e\u6d4e\u795e\u5dde\u3002\u5c3d\u7ba1\u9ed8\u514b\u7684Keytruda\u5728\u5e02\u573a\u4e0a\u5360\u4e3b\u5bfc\u5730\u4f4d\uff0c\u4f46\u5206\u6790\u5e08\u5bf9\u8fd9\u79cd\u836f\u7269\u7684\u8fc7\u5ea6\u4f9d\u8d56\u8868\u793a\u4e86\u62c5\u5fe7\u3002\u6709\u62a5\u544a\u6307\u51fa\uff0cKeytruda\u5e76\u6ca1\u6709\u5ef6\u957f\u5c0f\u7ec6\u80de\u80ba\u764c\uff08SCLC\uff09\u60a3\u8005\u7684\u5bff\u547d\uff0c\u4f46\u5b83\u4e0e\u5316\u7597\u8054\u5408\u4f7f\u7528\u786e\u5b9e\u53ef\u4ee5\u51cf\u7f13\u764c\u75c7\u7684\u8fdb\u5c55\u3002<\/p>\n<p>\u767e\u6d4e\u795e\u5dde\u7684Tislelizumab\u53ef\u80fd\u4f1a\u6210\u4e3a\u4e2d\u56fd\u5e02\u573a\u4e0a\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u7684\u66f4\u76f4\u63a5\u7ade\u4e89\u5bf9\u624b\uff0c\u5c3d\u7ba1\u9ed8\u514b\u53ef\u80fd\u4f1a\u5728\u4e24\u5e74\u5de6\u53f3\u7684\u65f6\u95f4\u91cc\u611f\u89c9\u4e0d\u5230\u8fd9\u79cd\u7ade\u4e89\u3002\u52302025\u5e74\uff0cKeytruda\u7684\u5e74\u9500\u552e\u989d\u9884\u8ba1\u5c06\u8fbe\u5230225\u4ebf\u7f8e\u5143\u7684\u5cf0\u503c\u3002<\/p>\n<p>\u82f1\u6587\u6765\u6e90\uff1aBiospace<\/p>\n","protected":false},"excerpt":{"rendered":"<p>BeiGene, with offices in Beijing, China and Cambridge, Massachusetts, announced results from its pivotal Phase III trial of its anti-PD-1 antibody tislelizumab in combination with two chemotherapy agents in squamous non-small cell lung cancer (NSCLC).<\/p>\n","protected":false},"author":9,"featured_media":314292,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[427],"tags":[820,747,925,459],"class_list":["post-314304","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-news-zh-hans","tag-820","tag-747","tag-925","tag-459","sectors-life-science-zh-hans","locations-china-zh-hans","locations-us-zh-hans"],"acf":[],"_links":{"self":[{"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/posts\/314304","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/comments?post=314304"}],"version-history":[{"count":0,"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/posts\/314304\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/media\/314292"}],"wp:attachment":[{"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/media?parent=314304"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/categories?post=314304"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/tags?post=314304"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}